Forge CEO Timothy J. Miller (center) with CWRU Forge Forward program leadership. (Photo: Business Wire)
With the goal of training and attracting top talent, Columbus-based gene therapy company Forge Biologics has launched the Forge Forward gene therapy workforce development program in partnership with the National Center for Regenerative Medicine (NCRM) at Case Western Reserve University, according to a news release.
Forge Biologics a gene therapy-focused contract development and manufacturing organization (CDMO) aims to attract talent with specialized Good Manufacturing Practice (GMP) training to the company in Columbus and beyond as it grows. The gene therapy manufacturing boom has created an unmet workforce demand whose training will be foundational for the success of the gene therapy industry, said Timothy J. Miller, CEO, president and co-founder of Forge, in a provided statement. We are especially excited to be partnering with the NCRM to help expand the talent pool o
Published: Jun 03, 2021
COLUMBUS, Ohio (BUSINESS WIRE) Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer. Mr. Maslowski brings significant gene therapy manufacturing and development experience to Forge as the Company has expanded its cGMP AAV manufacturing capabilities, including process and analytical development. As CCO, Mr. Maslowski will lead the Marketing, Sales, and Client Development departments to support our partners and clients on their path towards commercializing gene therapies.
John Maslowski, Chief Commercial Officer (Photo: Business Wire)
“We are excited to have John join the leadership team at such an important inflection point in the growth of Forge,” said Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics. “John is a seasoned biotech executive, bringing over 20 years o
Acting United States Attorney Richard G. Frohling announced that on April 27, 2021, a federal grand jury in the Eastern District of Wisconsin indicted Radomir Buzdum, formerly of Watertown, Wisconsin, and Timothy J. Miller, of Watertown, for offenses related to the operation of the TNT/Wild Rose strip club, which had been located in Lebanon (Dodge County), Wisconsin.
The indictment contains three counts. Count One alleges that between July 2012 and January 2019, Buzdum (the owner of the club) and Miller (a former manager) conspired with each other and others to use facilities in interstate commerce to promote, manage, and carry on unlawful prostitution offenses, in violation of Title 18, United States Code, Sections 371 & 1952(a)(3). According to the indictment, the purpose of the conspiracy was to generate revenue by making areas of the club for unlawful prostitution activity, including oral sex, full intercourse, and fetish activities. The indictment further alleges that members o
Acting United States Attorney Richard G. Frohling announced that on April 27, 2021, a federal grand jury in the Eastern District of Wisconsin indicted Radomir Buzdum, formerly of Watertown, Wisconsin, and Timothy J. Miller, of Watertown, for offenses related to the operation of the TNT / Wild Rose strip club, which had been located in Lebanon (Dodge County), Wisconsin.
The indictment contains three counts. Count One alleges that between July 2012 and January 2019, Buzdum (the owner of the club) and Miller (a former manager) conspired with each other and others to use facilities in interstate commerce to promote, manage, and carry on unlawful prostitution offenses, in violation of Title 18, United States Code, Sections 371 & 1952(a)(3). According to the indictment, the purpose of the conspiracy was to generate revenue by making areas of the club for unlawful prostitution activity, including oral sex, full intercourse, and fetish activities. The indictment further alleges that members
Published: Apr 29, 2021 By Alex Keown
Less than one year after
launching, Ohio-based Forge Biologics
secured $120 million in a Series B financing round to support the clinical development of its gene therapy program for rare diseases, including the typically fatal Krabbe disease.
In an announcement this morning,
Forge said the proceeds from the Series B program will be used to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity and operate its subsidiaries that are advancing novel AAV gene therapy programs. The company said it takes a “patient-first approach” in its mission to develop these gene therapy programs.